Immune boosting NK cells show promise in blood cancer trial

NCT ID NCT02727803

First seen Nov 06, 2025 · Last updated May 21, 2026 · Updated 20 times

Summary

This study tests whether giving patients their own specially matched natural killer (NK) cells after chemotherapy and a cord blood transplant can help keep blood cancers like leukemia and lymphoma from coming back. About 100 adults with various blood cancers will receive NK cells tailored to their immune type. The goal is to see if this approach improves how long patients live without their cancer progressing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

Conditions

Explore the condition pages connected to this study.

ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE ACUTE BIPHENOTYPIC LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES ACUTE MYELOID LEUKEMIA WITH VARIANT MLL TRANSLOCATIONS ACUTE MYELOID LEUKEMIA WITH VARIANT MLL TRANSLOCATIONS B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 CHEMOTHERAPY-RELATED LEUKEMIA CHRONIC MYELOMONOCYTIC LEUKEMIA CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS ISS STAGE II PLASMA CELL MYELOMA ISS STAGE II PLASMA CELL MYELOMA ISS STAGE III PLASMA CELL MYELOMA ISS STAGE III PLASMA CELL MYELOMA MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS MYELODYSPLASTIC SYNDROME WITH GENE MUTATION MYELODYSPLASTIC SYNDROME WITH GENE MUTATION MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROME RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT ADULT ACUTE MYELOID LEUKEMIA RECURRENT HODGKIN LYMPHOMA RECURRENT NON-HODGKIN LYMPHOMA REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY ADULT ACUTE LYMPHOBLASTIC LEUKEMIA SECONDARY ACUTE MYELOID LEUKEMIA SECONDARY ACUTE MYELOID LEUKEMIA THERAPY-RELATED MYELODYSPLASTIC SYNDROME THERAPY-RELATED MYELODYSPLASTIC SYNDROME